IL1B and neoplasm: Anakinra and other IL-1 signaling antagonists including canakinumab and rilonacept, prescribed for inflammatory conditions, have a remarkable safety record (79) and experimental evidence, across most cancer types, supports a tumor-promoting role for IL-1β (80–83).